Skip to main content

Table 1 Demographic and clinical data

From: Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients

Variables

N (%)

Variables

N (%)

Gender

Major surgery

 Female

40 (57.1)

No

60 (85.7)

 Male

30 (42.9)

Yes

10 (14.3)

Habits

Minor surgery

 Smokers

18 (25.7)

No

40 (57.1)

 Non-smokers

52 (74.3)

Yes

30 (42.9)

History of bilharziasis

Hazardous injection

 No

37 (52.9)

No

56 (80)

 Yes

33 (47.1)

Yes

14 (20)

Oral treatment (bilharziasis)

Diabetes

 No

44 (62.9)

No

50 (71.4)

 Yes

26 (37.1)

Yes

20 (28.6)

Parenteral treatment (bilharziasis)

HTN

 No

61 (87.1)

No

48 (68.6)

 Yes

9 (12.9)

Yes

22 (31.4)

Dental manipulations

Dyslipidemia

 No

30 (42.9)

No

60 (85.7)

 Yes

40 (57.1)

Yes

10 (14.3)

Blood transfusion

Hepatomegaly

 No

59 (84.3)

No

36 (51.4)

 Yes

11 (15.7)

Yes

34 (48.6)

Metabolic syndrome

 No

45 (64.3)

  

 Yes

25 (35.7)